Analyst Ratings For Davita Inc (NYSE:DVA)
Today, Davita Inc (NYSE:DVA) stock received an upgrade by JPMorgan Chase & Co. from Underweight to Neutral.
There are 5 Buy Ratings, 4 Hold Ratings, 1 Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Davita Inc (NYSE:DVA) is Buy with a consensus target price of $82.7143 per share, a potential 22.43% upside.
Some recent analyst ratings include
- 9/13/2018-Davita Inc (NYSE:DVA) gets upgraded to Neutral by JPMorgan Chase & Co.
- 6/6/2018-Davita Inc (NYSE:DVA) had its Buy rating reiterated by William Blair
- 2/14/2018-Davita Inc (NYSE:DVA) had its Hold rating reiterated by SunTrust Banks with a $80.00 price target
- 1/11/2018-Davita Inc (NYSE:DVA) had its Buy rating reiterated by Bank of America with a $92.00 price target
- 12/11/2017-Davita Inc (NYSE:DVA) gets upgraded to Buy by Citigroup with a price target of $82.00
- 12/7/2017-Davita Inc (NYSE:DVA) gets upgraded to Strong-Buy by Raymond James with a price target of $84.00
Recent Insider Trading Activity For Davita Inc (NYSE:DVA)
Davita Inc (NYSE:DVA) has insider ownership of 0.95% and institutional ownership of 87.80%.
- On 6/7/2018 Pamela M Arway, Director, sold 1,264 with an average share price of $68.76 per share and the total transaction amounting to $86,912.64.
- On 5/22/2018 William L Roper, Director, sold 1,505 with an average share price of $68.22 per share and the total transaction amounting to $102,671.10.
- On 5/14/2018 Charles Berg, Director, sold 338 with an average share price of $66.25 per share and the total transaction amounting to $22,392.50.
- On 1/16/2018 James K Hilger, Insider, sold 3,572 with an average share price of $78.95 per share and the total transaction amounting to $282,009.40.
- On 12/11/2017 Charles Berg, Insider, sold 7,048 with an average share price of $69.24 per share and the total transaction amounting to $488,003.52.
- On 12/8/2017 Kent J Thiry, Chairman, sold 81,800 with an average share price of $68.04 per share and the total transaction amounting to $5,565,672.00.
- On 12/8/2017 Leanne M Zumwalt, VP, sold 949 with an average share price of $68.19 per share and the total transaction amounting to $64,712.31.
About Davita Inc (NYSE:DVA)
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
Recent Trading Activity for Davita Inc (NYSE:DVA)
Shares of Davita Inc closed the previous trading session at 67,56 up +1,00 1,50 % with shares trading hands.
